Founded in 2017, we provide reliable and accurate cell based models for drug development.
Our mission is to accelerate new drug development by providing leading industry research organisations with a renewable, reliable source of functional liver tissue.
We have an ethnically diverse library of human hepatocytes that enables a preview of how compounds will react in clinical trials.
We will shortly be piloting the following liver-specific disease models:
NAFLD - Lipid loaded mini-liver tissues that mimic the fatty liver phenotype of early stage non-alcoholic fatty liver disease.
NASH - Test progression of disease from steatosis to inflammation and fibrosis in the best 3D in vitro human model for NASH.
Fibrosis - Screen and test efficacy of anti-fibrotic drugs in our powerful 3D in vitro model that reflects scarring observed in human liver fibrosis.
Cholestasis - Investigate the detection of cholestatic potential in our 3D in vitro model.